VIDEO: Studies improve understanding of advanced RAS wild-type colorectal cancer therapy

In this video, Christine M. Walko, PharmD, BCOP, FCCP, discussed four colorectal cancer presentations from ASCO Annual Meeting, including the phase 3 TRIPLETE study, phase 3 STRATEGIC-1 study, IMPROVE study and late-breaking PARADIGM trial.
"In general, all four of those abstracts — the three in my session and then PARADIGM — all helped us better understand, for our advanced RAS wild-type colorectal cancer patients, the value of utilizing anti-EGFR therapy up front," Walko, a personalized medicine specialist at DeBartolo Family Personalized Medicine Institute in Tampa, Florida,

In this video, Christine M. Walko, PharmD, BCOP, FCCP, discussed four colorectal cancer presentations from ASCO Annual Meeting, including the phase 3 TRIPLETE study, phase 3 STRATEGIC-1 study, IMPROVE study and late-breaking PARADIGM trial.
«In general, all four of those abstracts — the three in my session and then PARADIGM — all helped us better understand, for our advanced RAS wild-type colorectal cancer patients, the value of utilizing anti-EGFR therapy up front,» Walko, a personalized medicine specialist at DeBartolo Family Personalized Medicine Institute in Tampa, Florida,